Pembrolizumab is a humanised therapeutic antibody against the PD-1 receptor. It has been used in various advanced cancer immunotherapies. Here, we report an extremely rare case of a 32-year-old man who developed Stevens-Johnson syndrome (SJS) with porokeratosis simultaneously during pembrolizumab treatment for primary hepatocellular carcinoma (T3N1M1).
Keywords: PD-1 inhibitor; Stevens-Johnson syndrome; immune checkpoint inhibitors; pembrolizumab; porokeratosis; toxic epidermal necrolysis.
© 2021 The Australasian College of Dermatologists.